Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

246 results about "Fucosylation" patented technology

Fucosylation is the process of adding fucose sugar units to a molecule. It is a type of glycosylation. It is important clinically, and high levels of fucusylation have been reported in cancer. It is performed by fucosyltransferase enzymes.

Monoclonal antibodies against prostate specific membrane antigen (PSMA) lacking in fucosyl residues

The invention pertains to anti-PSMA antibodies that lack fucosyl residues. The antibodies of the invention exhibit increased antibody-dependent cellular cytotoxicity (ADCC) activity as compared to the fucosylated form of the antibodies. The invention also provides host cells that express the anti-PSMA antibodies that lack fucosyl residues, wherein the host cells are deficient for a fucosyl transferase. Methods of using the antibodies to inhibit the growth of PSMA+ cells, such as tumor cells, are also provided.
Owner:ER SQUIBB & SONS INC +1

Methods and compositions for producing double allele knock outs

The present invention provides a method and compositions utilizing the CRISPR system to disrupt a target gene in eukaryotic cells to produce double allele knock outs. The method finds use in producing afucosylated antibodies with enhanced ADCC activity.
Owner:LARIX BIOSCI

Prevention of opportunistic infections in immune-compromised subjects

This invention relates to a composition suitable for use in the prevention of opportunistic infections in immune-compromised individuals comprising a probiotic Bifidobacterium lactis, Bifidobacterium infantis, Bifidobacterium breve or Bifidobacterium longum and a fucosylated oligosaccharide selected from the group comprising 2′-fucosyllactose, 3′fucosyllactose, difucosyllactose, lacto-N-fucopentaose, lacto-N-fucohexaose, fucosyllacto-N-hexaose and fucosyllacto-N-neohexaose. The invention further extends to the use of such a composition in the prevention of opportunistic infections in immune-compromised individuals.
Owner:SOC DES PROD NESTLE SA

Methods of modulating fucosylation of glycoproteins

The present invention provides methods and materials useful for monitoring and regulating the glycosylation of glycoproteins that are recombinantly produced from cells. In particular, methods are provided for monitoring and regulating levels of cellular indicators which affect the level of fucosylation produced by cells.
Owner:MOMENTA PHARMA

Core fucosylated glycopeptides and glycoproteins: chemoenzymatic synthesis and uses thereof

ActiveUS20120226024A1Prolonged half-life-timeLess immunogenicityImmunoglobulins against animals/humansEnzymesFucosylationEndorhamnosidase
A chemoenzymatic method for the preparation of a core-fucoslyated glycoprotein or glycopeptide, including (a) providing an acceptor selected from the group consisting of a fucosylated GlcNAc-protein and fucosylated GlcNAc-peptide; and (b) reacting the acceptor with a donor substrate including an activated oligosaccharide moiety, in the presence of an endoglycosidase (ENGase) selected from Endo;F1, Endo-F2, Endo-F3, Endo-D and related glycosynthase mutants to transfer the oligosaccharide moiety to the acceptor and yield the structure defined core-fucosylated glycoprotein or glycopeptide. The donor substrate includes, in a specific implementation, a synthetic oligosaccharide oxazoline. A related method of fucosylated glycoprotein or fucosylated glycopeptide remodeling with a predetermined natural N-glycan or a tailor-made oligosaccharide moiety, and a method of remodeling an antibody to include a predetermined sugar chain to replace a heterogeneous sugar chain, are also described.
Owner:UNIV OF MARYLAND BALTIMORE

Glycan-optimized Anti-cd20 antibodies

Glycan-optimized monoclonal antibodies that specifically bind CD20 antigen and which have improved effector function are provided. The anti-CD20 antibodies of the invention have a glycosylation pattern that results in an antibody composition having predominately the G0 glycoform, and thus comprise N-glycans that lack fucose (i.e., afucosylated) and galactose residues attached thereto. In some embodiments, these anti-CD20 antibodies comprise the light chain and heavy chain sequences of the rituximab anti-CD20 antibody, and thus represent afucosylated rituximab. Methods for producing these glycan-optimized anti-CD20 antibodies are also provided.
Owner:SYNTHON BIOPHARMACEUTICALS BV

Chemoenzymatic glycoengineering of antibodies and fc fragments thereof

ActiveUS20150087814A1Reduced hydrolysis activityIncreased transglycosylation activityBacteriaMicroorganism based processesFucosylationFc domain
The present invention provides for recombinant Endo-S mutants that exhibit reduced hydrolysis activity and increased transglycosylation activity for the synthesis of glycoproteins wherein a desired sialylated oxazoline or synthetic oligosaccharide oxazoline is added to a core fucosylated or nonfucosylated GlcNAc-protein acceptor. Such recombinant Endo-S mutants are useful for efficient glycosylation remodeling of IgGl-Fc domain to provide different antibody glycoforms carrying structurally well-defined Fc N-glycans.
Owner:UNIV OF MARYLAND

Diagnosis of liver pathology through assessment of protein glycosylation

Methods for diagnosing pathology of the liver in a subject suspected of having such pathology are disclosed. The methods comprise quantifiably detecting glycosylation, and more specifically fucosylation, on proteins in biological fluids, and comparing the detected glycosylation with reference values for the glycosylation of such proteins in healthy or disease states.
Owner:DREXEL UNIV

Alpha (1,2) Fucosyltransferases Suitable for Use in the Production of Fucosylated Oligosaccharides

The invention provides compositions and methods for engineering E. coli or other host production bacterial strains to produce fucosylated oligosaccharides, and the use thereof in the prevention or treatment of infection.
Owner:GLYCOSYN

Genetic engineering cell line for producing unfucosylated protein and establishment method thereof

The invention discloses a genetic engineering cell line for producing an unfucosylated protein and an establishment method thereof. The invention utilizes the CRISPR / Cas9 technique to knock out the Slc35cl gene and / or the Fut8 gene in host cells, and thereby the Slc35cl gene-silencing and / or Fut8 gene-silencing stable genetic engineering cell line is obtained. By utilizing the genetic engineering cell line disclosed by the invention, the protein from which fucosylation is completely removed can be produced, moreover, the protein is still stable after 30 generations of passage, and thereby the two major problems of incomplete fucosylation removal and unstable passage in the prior art are solved. An unfucosylated antibody produced by the method disclosed by the invention shows enhanced ADCC (antibody dependent cell-mediated cytotoxicity) activity, and thereby the clinical therapeutic effect of the antibody is enhanced.
Owner:江苏东抗生物医药科技有限公司

Combination therapy of an anti cd20 antibody with a btk inhibitor

InactiveUS20150125446A1Enhanced antiproliferative effectGood effectAntibody ingredientsImmunoglobulinsFucosylationOncology
The present invention is directed to the combination therapy of an anti-CD20 antibody with a BTK inhibitor for the treatment of cancer, especially to the combination therapy of CD20 expressing cancers with a type I anti-CD20 antibody or an afucosylated humanized B-Ly1 antibody and a BTK inhibitor.
Owner:ONO PHARMA CO LTD +1

Antibody of fucosylated Golgi protein GP73 and use thereof

The invention relates to an antibody against fucosylated protein GP73, a method for preparing the antibody against the fucosylated protein GP73, a reagent for diagnosing liver cancers, a kit for diagnosing the liver cancers, application of the reagent and / or the kit to preparing products for diagnosing liver diseases and a method for preparing purified fucosylated protein GP73. Occurrence, development and metastasis of liver cancers are diagnosed by detecting the fucosylated protein GP73 or the antibody. The antibody against the fucosylated protein GP73 can be more widely used for affinity chromatography, cDNA library screening, immunologic diagnosis or pharmaceutical preparation.
Owner:THE INST OF BASIC MEDICAL SCI OF CHINESE ACAD OF MEDICAL SCI

Monoclonal antibodies against cd30 lacking in fucosyl and xylosyl residues

The invention pertains to anti-CD30 antibodies that lack fucosyl and xylosyl residues. The antibodies of the invention exhibit increased antibody-dependent cellular cytotoxicity (ADCC) activity, including the ability to lyse CD30-expressing cell lines that are not lysed by the fucosylated and xylosylated form of the antibodies. The invention also provides host cells that express the anti-CD30 antibodies that lack fucosyl and xylosyl residues, wherein the host cells are deficient for a fucosyltransferase and a xylosyltransferase. Methods of using the antibodies to inhibit the grown of CD30+ cells, such as tumor cells, are also provided.
Owner:BIOLEX THERAPEUTICS INC +2

Modified antibody, antibody-conjugate and process for the preparation thereof

The present invention relates to an antibody comprising a GlcNAc-S(A)x substituent, wherein S(A)x is a sugar derivative comprising x functional groups A wherein A is independently selected from the group consisting of an azido group, a keto group and an alkynyl group and x is 1, 2, 3 or 4, wherein said GlcNAc-S(A)x substituent is bonded to the antibody via CI of the N-acetylglucosamine of said GlcNAc-S(A)x substituent, and wherein said N-acetylglucosamine is optionally fucosylated. The invention also relates to an antibody-conjugate, in particular to an antibody-conjugate according to the Formula (20) or (20b), wherein AB is an antibody, S is a sugar or a sugar derivative, D is a molecule of interest, and wherein said N-acetylglucosamine is optionally fucosylated (b is 0 or 1). The invention further relates to a process for the preparation of a modified antibody, to a process for the preparation of an antibody-conjugate, and to said antibody-conjugate for use as a medicament. In addition, the invention relates to a kit of parts comprising an azide-modified antibody and a linker-conjugate, wherein said linker-conjugate comprises a (hetero)cycloalkynyl group and one or more molecules of interest.
Owner:SYNAFFIX

Fucosylated oligosaccharides and process for their preparation

The present invention relates to a process for the preparation of oligosaccharides or oligosaccharide containing compounds, especially N-acetyl-chitooligosaccharides having a fucosylated monosaccharide. The invention also relates to novel oligosaccharides or oligosaccharide containing compounds, especially N-acetyl-chitooligosaccharides, which are fucosylated and optionally covalently bound to a carrier molecule.
Owner:BIOTIE THERAPIES CORP

Monoclonal Antibodies Against Prostate Specific Membrane Antigen (PSMA) Lacking in Fucosyl Residues

The invention pertains to anti-PSMA antibodies that lack fucosyl residues. The antibodies of the invention exhibit increased antibody-dependent cellular cytotoxicity (ADCC) activity as compared to the fucosylated form of the antibodies. The invention also provides host cells that express the anti-PSMA antibodies that lack fucosyl residues, wherein the host cells are deficient for a fucosyl transferase. Methods of using the antibodies to inhibit the growth of PSMA+ cells, such as tumor cells, are also provided.
Owner:ER SQUIBB & SONS INC +1

Monoclonal antibodies against prostate specific membrane antigen (PSMA) lacking in fucosyl residues

The invention pertains to anti-PSMA antibodies that lack fucosyl residues. The antibodies of the invention exhibit increased antibody-dependent cellular cytotoxicity (ADCC) activity as compared to the fucosylated form of the antibodies. The invention also provides host cells that express the anti-PSMA antibodies that lack fucosyl residues, wherein the host cells are deficient for a fucosyl transferase. Methods of using the antibodies to inhibit the growth of PSMA+ cells, such as tumor cells, are also provided.
Owner:ER SQUIBB & SONS INC

Modified glycoprotein, protein-conjugate and process for the preparation thereof

Glycoproteins comprising a glycan of the formula (102) are disclosed; wherein b is 0 or 1; the GlcNAc residue optionally fucosylated; and Su(A)x is a sugar derivative comprising x functional groups A, wherein x is 1, 2, 3 or 4 and A is independently selected from the group consisting of an azido group, a keto group, an alkynyl group, a thiol group, a halogen, a sulfonyloxy group, a halogenated acetamido group, a mercaptoacetamido group and a sulfonylated hydroxyacetamido group.Protein-conjugates having glycoproteins according to the invention conjugated to a molecule of interest (e.g., an active substance) are also disclosed. Examples include modified antibodies, antibody-conjugates, and antibody-drug conjugates (ADCs). Processes for the preparation of the modified glycoproteins according to the invention and methods for the preparation of a protein-conjugate according to the invention are mentioned.
Owner:SYNAFFIX

Diagnosis of liver pathology through assessment of protein glycosylation

Methods for diagnosing pathology of the liver in a subject suspected of having such pathology are disclosed. The methods comprise quantifiably detecting glycosylation, and more specifically fucosylation, on proteins in biological fluids, and comparing the detected glycosylation with reference values for the glycosylation of such proteins in healthy or disease states.
Owner:DREXEL UNIV

Alpha (1,2) fucosyltransferases suitable for use in the production of fucosylated oligosaccharides

The invention provides compositions and methods for engineering E. coli or other host production bacterial strains to produce fucosylated oligosaccharides, and the use thereof in the prevention or treatment of infection.
Owner:GLYCOSYN

Hematopoietic stem cells treated by in vitro fucosylation and methods of use

A method of in vitro fucosylation of selectin ligands on cord blood-derived hematopoietic stem cells for bone marrow transplantation is disclosed. In this method, an effective amount of an α1,3-fucosyltransferase, e.g., α1,3-fucosyltransferase VI, is used in vitro to treat cord blood-derived hematopoietic stem cells to convert non-functional PSGL-1 or other ligands on the cell surface into functional forms that bind selectins, especially P-selectin or E-selectin. The treated cells have enhanced effectiveness in reconstituting bone marrow in patients in need of such therapy.
Owner:OKLAHOMA MEDICAL RES FOUND

Plant production of immunoglobulins with reduced fucosylation

This invention provides for the plant production of immunoglobulins, wherein at least a portion of the glycans attached to the immunoglobulins lack fucose. The invention also provides the constructs; plasmids; vectors; transformed plant cells, transformed plant calli; transformed plant tissues (e.g., leaves, seeds, tubers, etc.); transformed whole plants used to produce such immunoglobulins; methods of producing the immunoglobulins; the immunoglobulins produced by the disclosed methods; and the use of such immunoglobulins.
Owner:PHYTON HLDG

Novel fucosyltransferases and their applications

The present invention relates to nucleic acid and amino acid sequences from Akkermansia muciniphila and from Bacteroides fragilis, coding for / representing novel alpha-1,3-fucosyltransferases. The invention also provides uses and methods for using the alpha-1,3-fucosyltransferases to generate fucosylated products, such as oligosaccharides, (glyco)proteins, or (glyco)lipids, in particular of 3-fucosyllactose.
Owner:CHR HANSEN HMO GMBH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products